What’s New in Weight Loss in 2026: New Methods, What’s Proven and What’s Hype

laboratory, analysis, chemistry, research, chemist, lab, phd, diagnostics, hospital, test tubes, medical, doctor, medic, tests, treatment, diagnostici

Written by

marketing

in

,

What's new

What is new in weight loss in 2026: GLP-1 pills, Wegovy HD, Foundayo, lower prices and the Medicare bridge (proven); CagriSema and retatrutide (promising); microdosing and research peptides (hype).

By marketing Updated October 7, 2026 Facts checked October 6, 2026

Fact-checked against FDA labels and official sources; not yet reviewed by a licensed clinician. This page is education, not medical advice. Talk to your doctor before starting, stopping or changing any treatment.

Key takeaways

  • Two GLP-1 weight-loss pills were approved within four months: Wegovy tablets (December 22, 2025) and Foundayo (April 1, 2026).[3]
  • Wegovy HD (7.2 mg) was approved on March 19, 2026, with -18.8% vs -3.9% average weight change in its 72-week label trial.[5]
  • The Medicare GLP-1 Bridge offers Wegovy, Zepbound KwikPen and Foundayo for a $50 copay from July 2026 to December 2027 for people who meet its criteria.[14]
  • CagriSema, retatrutide and amylin-based drugs showed strong trial results but are investigational, not FDA approved.[22]
  • Compounded GLP-1s are not FDA approved, and "research peptide" versions of investigational drugs cannot legally be compounded.[29]

In short: The biggest real changes in 2026 so far are new FDA-approved options and new ways to pay for them: the first GLP-1 weight-loss pills (Wegovy tablets in December 2025 and Foundayo in April 2026), a higher Wegovy dose (Wegovy HD), lower self-pay prices and a Medicare bridge program with a $50 copay. Several investigational medicines, such as CagriSema, retatrutide and amylin-based drugs, posted strong trial results but are not approved. And some of the loudest trends, such as compounded “microdoses”, “research peptides” and “Nature’s Ozempic” supplements, lack the evidence or approval to back them. Everything below was checked on October 6, 2026.

We sort each development into one of three groups. Proven means FDA approved, or backed by a national guideline. Promising means good trial results but not approved yet. Hype means it is marketed widely without approval or solid evidence. For the full list of established options, see 40 ways to lose weight compared; for this month’s news, the October 2026 roundup.

2026 at a glance

  • 2GLP-1 pills approved for weight within four months: Wegovy tablets (Dec 22, 2025) and Foundayo (Apr 1, 2026)Drugs@FDA
  • $149lowest maker self-pay price for a month of a GLP-1 pill (lowest strengths)NovoCare; Lilly
  • $50Medicare GLP-1 Bridge copay, July 2026 to December 2027CMS
  • 0new medicines approved so far from the amylin or triple-agonist classes

Checked on October 6, 2026

Proven: what is new and FDA approved

The first GLP-1 weight-loss pills. Wegovy tablets (oral semaglutide 25 mg) were approved on December 22, 2025, for weight management and heart-risk reduction in adults. They are taken each morning on an empty stomach with up to 4 ounces of water, followed by a 30-minute wait. In the label trial, average weight change at 64 weeks was -13.6% vs -2.4% with placebo. Foundayo (orforglipron) followed on April 1, 2026, the first new molecular entity approved under the FDA’s national priority voucher pilot. It is a once-daily small-molecule pill that can be taken with or without food, and its label trial showed -11.1% vs -2.1% at the highest dose over 72 weeks. Our oral GLP-1 guide compares the two.

A higher Wegovy dose. On March 19, 2026, the FDA approved a 7.2 mg weekly dose, sold as Wegovy HD, for adults who have tolerated 2.4 mg for at least four weeks. In its 72-week label trial, average weight change was -18.8% vs -3.9% with placebo, with more nausea and a tingling or burning skin feeling (dysesthesia) reported in 22% of people vs 6% on 2.4 mg.

Newly approved options: average weight change in their label trialsValues in %
Newly approved options: average weight change in their label trials
ItemMedicinePlacebo
Foundayo (72 wk)11.1%2.1%
Wegovy HD 7.2 mg (72 wk)18.8%3.9%
Wegovy tablets (64 wk)13.6%2.4%

Separate placebo-controlled trials; not head-to-head. Alphabetical. Bars show percent of body weight lost.

Source: FDA labels on DailyMed (Foundayo; Wegovy injection and tablets) (checked on October 6, 2026)

Generic liraglutide. DailyMed now lists generic liraglutide injection labels from several companies; the ones we read carry the same weight indication as Saxenda, including for teens 12 and older with obesity and a body weight over 60 kg. Liraglutide is a daily injection with smaller average losses than the newer weekly medicines (-7.4% vs -3.0% in its 56-week label trial). See liraglutide.

A safety label change. On January 13, 2026, after reviewing 91 trials, the FDA asked the makers of Saxenda, Wegovy and Zepbound to remove the warning about suicidal behavior and ideation from their labels, saying its review did not find an increased risk. Other warnings remain; our GLP-1 side effects guide covers them.

New ways to pay. Makers now sell directly at self-pay prices: as of October 6, 2026, Wegovy tablets are $149 to $299 a month and pens $349, Zepbound KwikPen $299 to $449 and Foundayo $149 to $349, by strength. Novo has also announced that Wegovy’s list price will fall to $675 a month from January 1, 2027. For people with Medicare, the CMS GLP-1 Bridge (July 1, 2026 to December 31, 2027) covers Wegovy, Zepbound KwikPen and Foundayo for a $50 copay for those who meet its criteria. Our insurance guide and cost hub explain the details.

More focus on protecting muscle. The 2026 American Diabetes Association Standards of Care advise optimizing protein intake alongside resistance training to preserve lean mass during weight loss treatment, building on a 2025 joint nutrition advisory from four obesity and nutrition societies. The new Dietary Guidelines for Americans, 2025-2030, released in January 2026, promote 1.2 to 1.6 grams of protein per kilogram of body weight a day. Our muscle loss guide and protein calculator put this into practice.

Promising: strong trials, not approved yet

CagriSema combines semaglutide with cagrilintide, an amylin receptor agonist. In REDEFINE 1, average weight change at 68 weeks was -20.4% vs -3.0% with placebo, but in the head-to-head REDEFINE 4 trial it did not match tirzepatide 15 mg (-20.2% vs -23.6%, company-reported). Novo filed with the FDA in December 2025. Our CagriSema explainer covers it in depth.

Retatrutide acts on three hormone receptors (GIP, GLP-1 and glucagon). In TRIUMPH-1, published in 2026, 2,339 adults lost on average 17.6%, 23.7% and 25.0% by dose vs 3.9% with placebo over 80 weeks; in TRIUMPH-2, in people with type 2 diabetes, up to 18.8% vs 5.1%. Lilly says it plans to submit it to the FDA in the first quarter of 2027.

Amylin-based medicines are the newest wave. Eloralintide, a selective amylin agonist, produced up to 20% loss vs 0.4% with placebo in a 48-week Phase 2 trial (assuming people stayed on treatment), and Lilly reported up to 23.3% with an eloralintide-tirzepatide combination in people with type 2 diabetes in September 2026. MariTide, an Amgen antibody-peptide drug injected every four weeks or less often in trials, averaged -12.3% to -16.2% vs -2.5% at 52 weeks in Phase 2. Our emerging medications page tracks twelve candidates.

Highest average weight loss reported for investigational candidates (not comparable)Values in %
Highest average weight loss reported for investigational candidates (not comparable)
ItemValue
CagriSema (REDEFINE 1, 68 wk)20.4%
Eloralintide (Phase 2, 48 wk)20%
MariTide (Phase 2, 52 wk)16.2%
Retatrutide (TRIUMPH-1, 80 wk)25%

INVESTIGATIONAL. Alphabetical. Different trials, lengths and estimands (eloralintide assumes everyone stayed on treatment); placebo results not shown. Not a ranking.

Source: NEJM 2025 and 2026; Lancet 2025 (see references) (checked on October 6, 2026)

Compounded GLP-1s after the shortages. The semaglutide and tirzepatide shortages ended in 2025 and 2024. On February 6, 2026, the FDA said it intends to act against non-approved GLP-1 drugs mass-marketed as alternatives to approved ones, and on April 30, 2026 it proposed excluding semaglutide, tirzepatide and liraglutide from the list of bulk ingredients outsourcing facilities may use (still a proposal when we checked). The FDA says compounded drugs are not FDA approved and has received hundreds of adverse-event reports, including dosing errors. Read compounded GLP-1s.

“Microdosing”. Some programs market very small GLP-1 doses. FDA labels list the approved strengths and dose steps; a microdose plan is not an FDA-approved regimen, and we found no large trials of it. The ADA does say a person’s best dose may not be the highest approved one, which is a different idea: adjusting within the label with your clinician.

“Research peptides”. Retatrutide and cagrilintide are investigational. The FDA says they cannot be used in compounding, and it warns that products sold “for research purposes” or “not for human consumption” may contain the wrong ingredient, the wrong amount or contaminants.

“Nature’s Ozempic”. Supplements such as berberine are marketed as natural GLP-1 alternatives. A 2026 meta-analysis found berberine lowered weight by 0.88 kg (about 2 lb) more than placebo, compared with 12.7 kg more for semaglutide in STEP 1. See berberine.

Hidden drugs. In September 2026, the FDA warned consumers not to use LUZE Fit Intensity, a product promoted for weight loss that contained sibutramine, a drug withdrawn from the U.S. market in 2010. Our supplements guide explains how to spot risky products.

Timeline: late 2025 to 2027

DateWhat happenedBadge
December 22, 2025FDA approves Wegovy tablets for weight managementProven
January 2026Dietary Guidelines for Americans, 2025-2030 releasedProven
January 13, 2026FDA requests removal of the suicidal behavior and ideation warning from GLP-1 weight-loss labelsProven
February 6, 2026FDA announces action against non-approved GLP-1s marketed as alternativesHype check
February 23, 2026CagriSema misses its head-to-head goal against tirzepatide (company-reported)Promising
March 19, 2026FDA approves Wegovy 7.2 mg (Wegovy HD)Proven
April 1, 2026FDA approves Foundayo (orforglipron)Proven
April 30, 2026FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listHype check
July 1, 2026Medicare GLP-1 Bridge starts ($50 copay)Proven
September 2026Retatrutide, CagriSema and EloraTZP data at the EASD meetingPromising
Q4 2026 (expected)FDA decision on CagriSemaPromising
January 1, 2027Wegovy list price set to drop to $675 a monthProven (announced)
Q1 2027 (planned)Lilly’s planned FDA submission for retatrutidePromising
FDA, CMS and company sources checked on 2026-10-06. Expected and planned dates are the companies’ own.

Who the new approvals are for

New does not mean for everyone. Wegovy tablets, Wegovy HD and Foundayo are labeled for adults only, with obesity, or with overweight and at least one weight-related condition, alongside a reduced-calorie diet and more activity. Wegovy HD is only for adults who have already tolerated the 2.4 mg dose for at least four weeks. The Wegovy injection at 2.4 mg and Saxenda, including its new generics, remain the GLP-1 options labeled for some teens aged 12 and older. Each label also lists people who should not use the medicine, such as those with a personal or family history of medullary thyroid carcinoma. A pill is not automatically easier, either: Wegovy tablets have a strict empty-stomach routine, while Foundayo can be taken with or without food. Our medication comparison sets the rules side by side.

Coverage is the other half of access. The Medicare GLP-1 Bridge has its own BMI and health criteria, many private plans still require prior authorization or do not cover weight medicines, and maker self-pay offers often exclude people with government insurance. Before switching to something new, check what your plan pays for.

What has not changed

For all the new medicines, the foundations are the same as last year. Every label still pairs the medicine with a reduced-calorie diet and more activity. Diets with similar calories still give similar results, as the DIETFITS trial showed. U.S. guidelines still recommend 150 to 300 minutes of moderate activity a week plus strength training on two days, and structured behavioral programs still often bring 5% to 10% loss. Weight still tends to return when people stop GLP-1 medicines, which is why the ADA now says long-term obesity medicines should be continued beyond reaching weight goals. Our how to lose weight guide and keeping weight off guide cover these basics.

How to use this year’s news

Making sense of a new headline

  1. Check the statusIs it FDA approved, or still investigational? Look for the label on DailyMed.
  2. Check the comparisonWas it tested against placebo or against an approved option?
  3. Check the sourceA peer-reviewed paper, or a company announcement?
  4. Ask your clinicianWhether anything new fits you better than what is available now.

If you are considering any of the approved medicines, our comparison of every FDA-approved weight-loss medication and the printable questions to ask before starting a GLP-1 are good next steps. For movement that helps protect muscle on any plan, see our exercise hub.

Records in this article

FDA approved for weight managementPrescriptionPillWegovy Pill (oral semaglutide): status, how it is taken, how it comparesSemaglutide: one ingredient, several brands · Pill (tablet) · DailyFDA approved for weight managementPrescriptionInjectionSemaglutide: one ingredient, several brandsInjection · Daily, WeeklyFDA approved for weight managementPrescriptionInjectionWegovy (semaglutide): uses, side effects, cost and FDA statusSemaglutide: one ingredient, several brands · Injection · WeeklyFDA approved for weight managementPrescriptionInjectionZepbound (tirzepatide): uses, side effects, cost and FDA statusTirzepatide: how the dual GIP/GLP-1 drug works (Zepbound, Mounjaro) · Injection · WeeklyStrength Training for Weight Loss: keep muscle while losing fatModerate · Low impactDietary supplement: not FDA approvedEvidence: LimitedBerberine for Weight Loss: evidence, risks and interactionsEvidence: Limited

Related guides

Online Dietitian Services Compared: Insurance, Cost and What’s IncludedFive online dietitian services compared, alphabetical and not ranked: insurance, self-pay prices, visit length, messaging, states…GLP-1 Medication vs a Diet Program: Results, Costs and Trade-offsGLP-1 medication vs a diet program compared: average weight loss in STEP, SURMOUNT, Look AHEAD and…Ozempic vs Mounjaro: How the Two Diabetes Drugs DifferOzempic vs Mounjaro compared from the FDA labels and the SURPASS-2 head-to-head trial: approved uses, how…Does Insurance Cover GLP-1s for Weight Loss? (checked quarterly)Does insurance cover GLP-1s for weight loss? Employer data, Medicare rules and the $50 GLP-1 Bridge,…

Questions to ask a professional

  • Does any of the newly approved options fit my health and preferences better than what I use now?
  • Would a pill or a weekly injection work better for my routine?
  • Am I eligible for the Medicare GLP-1 Bridge or other coverage?
  • Should I consider a clinical trial of a new medicine?

Frequently asked questions

What is the newest weight-loss medication?

The newest FDA approval for weight management is Foundayo (orforglipron), a daily GLP-1 pill approved on April 1, 2026. Wegovy HD, a 7.2 mg weekly dose of semaglutide, was approved on March 19, 2026.

Is there a weight-loss pill like Ozempic?

Yes. Wegovy tablets contain semaglutide, the same ingredient as Ozempic and Wegovy, and were approved for weight management in December 2025. Foundayo is a different GLP-1 pill approved in April 2026.

When will CagriSema and retatrutide be available?

Neither is approved. Novo Nordisk expects an FDA decision on CagriSema in the fourth quarter of 2026, and Lilly plans to submit retatrutide to the FDA in the first quarter of 2027. An FDA decision can go either way.

Is GLP-1 microdosing safe?

Microdosing is not an FDA-approved regimen, and we found no large trials of it. FDA labels list the approved strengths and dose steps. Talk with your clinician about adjusting a dose within the label.

Do "Nature's Ozempic" supplements work?

The evidence is weak. A 2026 meta-analysis found berberine lowered weight by about 0.88 kg (2 lb) more than placebo, far less than approved GLP-1 medicines.

References

  1. Drugs@FDA: Wegovy tablets, NDA 218316. U.S. Food and Drug Administration. (accessed October 7, 2026) Government page
  2. Drugs@FDA: Wegovy, NDA 215256, approval history. U.S. Food and Drug Administration. (accessed October 7, 2026) Government page
  3. Drugs@FDA: Foundayo, NDA 220934. U.S. Food and Drug Administration. (accessed October 7, 2026) Government page
  4. FDA Approves First New Molecular Entity Under National Priority Voucher Program. U.S. Food and Drug Administration, 2026. (accessed October 7, 2026) Government page
  5. WEGOVY (semaglutide) injection and tablets: prescribing information. Novo Nordisk, via DailyMed, 2026. (accessed October 7, 2026) Drug label
  6. FOUNDAYO (orforglipron) tablets: prescribing information. Eli Lilly and Company, via DailyMed, 2026. (accessed October 7, 2026) Drug label
  7. Liraglutide injection (Teva): prescribing information. Teva Pharmaceuticals; DailyMed (NLM), 2026. (accessed October 6, 2026) Drug label
  8. SAXENDA (liraglutide) injection: prescribing information. Novo Nordisk, via DailyMed, 2026. (accessed October 6, 2026) Drug label
  9. FDA requests removal of suicidal behavior and ideation warning from GLP-1 receptor agonist medications. U.S. Food and Drug Administration, 2026. (accessed October 6, 2026) Government page
  10. Wegovy at NovoCare Pharmacy: self-pay prices. Novo Nordisk (NovoCare Pharmacy). (accessed October 7, 2026) Other
  11. Zepbound coverage and savings. Eli Lilly and Company. (accessed October 6, 2026) Other
  12. Foundayo coverage and savings. Eli Lilly and Company. (accessed October 6, 2026) Other
  13. Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic and Rybelsus. Novo Nordisk (press release), 2026. (accessed October 7, 2026) News (reported facts only)
  14. Medicare GLP-1 Bridge: information for providers. Centers for Medicare and Medicaid Services. (accessed October 7, 2026) Government page
  15. 8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes, 2026. Diabetes Care; American Diabetes Association Professional Practice Committee, 2026. doi:10.2337/dc26-S008 · PMID 41358882 (accessed October 6, 2026) Guideline
  16. Mozaffarian D, Agarwal M, Aggarwal M, et al.. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. American Journal of Clinical Nutrition, 2025. doi:10.1016/j.ajcnut.2025.04.023 · PMID 40450457 (accessed October 6, 2026) Society statement
  17. Dietary Guidelines for Americans, 2025-2030. U.S. Department of Health and Human Services and U.S. Department of Agriculture, 2026. (accessed October 6, 2026) Guideline
  18. Pasiakos SM, Davis TA, Klurfeld DM, Neuhouser ML, Rodriguez NR, Tomé D. Perspectives on the Protein Recommendations in the 2025-2030 Dietary Guidelines for Americans. Journal of Nutrition, 2026. doi:10.1016/j.tjnut.2026.101754 · PMID 42498030 (accessed October 6, 2026) Review
  19. Garvey WT, Bluher M, Osorto Contreras CK, et al.. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). New England Journal of Medicine, 2025. doi:10.1056/NEJMoa2502081 · PMID 40544433 · NCT05567796 (accessed October 7, 2026) Randomized trial
  20. CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity; the primary endpoint was not achieved (company announcement). Novo Nordisk A/S, 2026. (accessed October 7, 2026) News (reported facts only)
  21. Novo’s investigational obesity and diabetes drug CagriSema reduces “food noise” and shows benefits in organ and bone health (EASD 2026). Novo Nordisk A/S, 2026. (accessed October 7, 2026) News (reported facts only)
  22. Jastreboff AM, Kaplan LM, Davies MJ, et al.. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1). New England Journal of Medicine, 2026. doi:10.1056/NEJMoa2604169 · PMID 42814954 · NCT05929066 (accessed October 7, 2026) Randomized trial
  23. Bellido V, le Roux CW, Ekinci EI, et al.. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2). The Lancet, 2026. doi:10.1016/S0140-6736(26)01861-1 · PMID 42810372 · NCT05929079 (accessed October 7, 2026) Randomized trial
  24. Lilly’s triple agonist, retatrutide, delivered substantial weight loss and A1C reduction (BLA planned Q1 2027). Eli Lilly and Company (press release), 2026. (accessed October 7, 2026) News (reported facts only)
  25. Billings LK, Hsia S, Bays H, et al.. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2 trial. The Lancet, 2025. doi:10.1016/S0140-6736(25)02155-5 · PMID 41207310 (accessed October 6, 2026) Randomized trial
  26. Lilly EloraTZP Phase 2b results (company announcement). Eli Lilly and Company, 2026. (accessed October 6, 2026) News (reported facts only)
  27. Jastreboff AM, Ryan DH, Bays HE, et al.. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity: A Phase 2 Trial. New England Journal of Medicine, 2025. doi:10.1056/NEJMoa2504214 · PMID 40549887 · NCT05669599 (accessed October 7, 2026) Randomized trial
  28. Novo Nordisk and Hengrui Pharma license agreement for HRS-1596. Novo Nordisk A/S, 2026. (accessed October 6, 2026) News (reported facts only)
  29. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. U.S. Food and Drug Administration, 2026. (accessed October 7, 2026) Government page
  30. FDA intends to take action against non-FDA-approved GLP-1 drugs. U.S. Food and Drug Administration, 2026. (accessed October 6, 2026) Government page
  31. FDA proposes to exclude semaglutide, tirzepatide and liraglutide from 503B bulks list. U.S. Food and Drug Administration, 2026. (accessed October 6, 2026) Government page
  32. Elahi Vahed I, Shahir-Roudi E, Nojumi S, et al.. The effect of berberine on obesity indices: a systematic review and meta-analysis. International Journal of Obesity, 2026. doi:10.1038/s41366-025-01943-x · PMID 41310257 (accessed October 6, 2026) Meta-analysis
  33. Wilding JPH, Batterham RL, Calanna S, et al.. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021. doi:10.1056/NEJMoa2032183 · PMID 33567185 · NCT03548935 (accessed October 7, 2026) Randomized trial
  34. FDA notification: weight-loss product may be harmful due to hidden ingredient (sibutramine). U.S. Food and Drug Administration, 2026. (accessed October 6, 2026) Government page
  35. Gardner CD, Trepanowski JF, Del Gobbo LC, et al.. Effect of Low-Fat vs Low-Carbohydrate Diet on 12-Month Weight Loss in Overweight Adults (DIETFITS randomized clinical trial). JAMA, 2018. doi:10.1001/jama.2018.0245 · PMID 29466592 · NCT01826591 (accessed October 7, 2026) Randomized trial
  36. Elmaleh-Sachs A, Schwartz JL, Bramante CT, et al.. Obesity Management in Adults: A Review. JAMA, 2023. doi:10.1001/jama.2023.19897 · PMID 38015216 (accessed October 6, 2026) Review
  37. Physical Activity Guidelines for Americans, 2nd edition: top 10 things to know. U.S. Department of Health and Human Services (ODPHP). (accessed October 7, 2026) Guideline

Facts checked on October 6, 2026

Educational information, not medical advice. Talk with a qualified healthcare professional about your own situation. In an emergency call 911.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

More posts